Clinical Trial Results:
A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid
Leukemia Resistant to or Intolerant of Imatinib Mesylate
Revised Protocol 01: Incorporates Amendment 03 and Administrative Letter dated 01-March-2005.
Amendment 01 country specific version 1.0 dated 2005-03-14
Summary
|
|
EudraCT number |
2004-002515-89 |
Trial protocol |
SE AT FI GB IT DE BE DK |
Global completion date |
03 Aug 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Dec 2016
|
First version publication date |
07 Dec 2016
|
Other versions |
|
Summary report(s) |
CA180-005_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.